Compare MVST & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MVST | AMRN |
|---|---|---|
| Founded | 2006 | 1989 |
| Country | United States | Ireland |
| Employees | 1908 | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 245.1M | 287.9M |
| IPO Year | 2019 | 1998 |
| Metric | MVST | AMRN |
|---|---|---|
| Price | $0.65 | $13.41 |
| Analyst Decision | Strong Buy | Strong Sell |
| Analyst Count | 1 | 1 |
| Target Price | $6.00 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 6.9M | 79.0K |
| Earning Date | 05-11-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 85.25 | 55.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $427,516,000.00 | $181,104,000.00 |
| Revenue This Year | $24.55 | N/A |
| Revenue Next Year | $17.08 | $1.26 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 12.56 | ★ 39.22 |
| 52 Week Low | $0.56 | $12.96 |
| 52 Week High | $7.12 | $20.90 |
| Indicator | MVST | AMRN |
|---|---|---|
| Relative Strength Index (RSI) | 41.48 | 37.81 |
| Support Level | N/A | N/A |
| Resistance Level | $1.02 | $14.50 |
| Average True Range (ATR) | 0.04 | 0.39 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 56.33 | 16.60 |
Microvast Holdings Inc develops lithium-ion battery technologies focused on high-performance solutions for commercial and industrial electrification. The Company designs, develops, and manufactures battery components and systems for electric commercial vehicles and energy storage systems (ESS), with applications across buses, trucks, port equipment, and mining machinery. It emphasizes innovation in battery design without relying on legacy technologies and supports platforms such as the IVECO eDaily and various bus models. The Company also provides services, repairs, and warranty and extended warranty support. It operates as a single reportable segment, covering design, development, manufacturing, sales, and leasing of battery systems, and generates the majority of its revenue from Europe.
Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States.